Immodulon is an independent biopharmaceutical company pioneering gentle immunotherapy treatments, in particular for cancer.
Immunotherapy is now recognised as the biggest breakthrough since chemotherapy in the treatment of cancer. Immodulon’s research demonstrates that its lead product is potentially transformational in improving the overal outcome for patients by use in combination with other anti-cancer treatments.
IMM‑101 is a naturally derived medical treatment that helps the body’s immune system to recognise and control cancer. It works in combination with other anti-cancer treatments to improve the overall outcome for patients. Clinical studies indicate that IMM‑101 has a potentially transformational impact on survival rates for cancer.
Immodulon is a small, independent biopharmaceutical company that has attracted significant investment to date, predominately from High Net Worth Individuals and impact investors.
Latest News & Research
News27 March 2017CityEye Blog Profile InterviewRead more
News27 March 2017Immodulon named in top 30 philanthropic UK companiesRead more
Events27 March 2017Immodulon attend BIA workshop on shaping the Industrial StrategyRead more
Events20 March 2017Speaking at ATPRead more
News20 March 2017Immodulon Trip to JapanRead more